Religo
January 19, 2024
Introduction:
Are you a pharmaceutical company struggling to keep up with the latest local literature?
Introducing DrugCard, the AI-enabled tool designed to revolutionize local literature screening in the pharmaceutical industry.
With DrugCard, you can streamline your drug safety routines and ensure compliance with regulatory requirements.
Stay up-to-date with the latest literature in your local markets through continuous and regular screening.
Track the screening process with traceability and transparency, ensuring accuracy, completeness, and a holistic approach.
Expand your operations globally with DrugCard’s scalability to new markets, supporting multiple languages and suppliers.
Experience a cost-effective solution that doesn’t require heavy capital investments.
Benefit from extensive coverage with over 100 supported languages and medical journals from over 35 countries.
Catering to different users within the pharmaceutical industry, DrugCard empowers CROs, MAHs, and freelancers alike.
Manage more projects, mitigate risks, and save time on literature screening with DrugCard.
Discover a reliable and efficient solution for local literature screening, meeting regulatory requirements with ease.
Overview:
DrugCard is an AI-enabled tool that specializes in local literature screening for the pharmaceutical industry. It is designed to streamline drug safety routines and ensure compliance with regulatory requirements. The tool offers continuous and regular screening, allowing pharmaceutical companies to stay up-to-date with the latest literature in their local markets. It provides traceability and transparency, allowing users to track the screening process and ensuring that it is accurate, complete, and holistic.
DrugCard is scalable to new markets, making it suitable for companies looking to expand their operations globally. It supports multiple languages and suppliers, allowing for a comprehensive screening process. One key advantage of DrugCard is that it does not require heavy capital investments, making it a cost-effective solution for pharmaceutical companies. The platform supports over 100 languages and covers medical journals from over 35 countries, providing extensive coverage for screening. It boasts a high accuracy rate in scanned PDF screening.
DrugCard caters to different users within the pharmaceutical industry, including Contract Research Organizations (CROs), Marketing Authorization Holders (MAHs), and freelancers. It enables CROs to manage more projects and improve screening results, while MAHs can choose to perform in-house screening to mitigate compliance and reputation risks. Freelancers can also benefit from the tool by saving time on literature screening and focusing on other value-adding activities.
Overall, DrugCard offers a reliable and efficient solution for local literature screening, providing the pharmaceutical industry with the necessary tools to streamline drug safety processes and meet regulatory requirements.
Benefits:
- Continuous and regular screening to stay up-to-date with the latest literature in local markets
- Traceability and transparency in the screening process for accuracy, completeness, and holistic approach
- Scalability to new markets, making it suitable for global expansion
- Cost-effective solution without heavy capital investments
- Support for over 100 languages and coverage of medical journals from over 35 countries
- High accuracy rate in scanned PDF screening
- Caters to different users within the pharmaceutical industry, including CROs, MAHs, and freelancers
- Enables CROs to manage more projects and improve screening results
- Allows MAHs to perform in-house screening to mitigate compliance and reputation risks
- Saves time for freelancers on literature screening, allowing them to focus on other value-adding activities
- Reliable and efficient solution for local literature screening to streamline drug safety processes and meet regulatory requirements
Get Exclusive AI Tips right in your inbox!
Receive the same AI tips that helped me to make $37,605 in just two weeks!
We promise we won’t spam your inbox.
